| Drug Type Biosimilar, Monoclonal antibody | 
| Synonyms Trastuzumab Biosimilar (Xeris Pharmaceuticals, Inc.), 曲妥珠单抗生物类似药(Xeris Pharmaceuticals, Inc.) | 
| Target | 
| Action antagonists | 
| Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePendingPreclinical | 
| First Approval Date- | 
| Regulation- | 


| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | - | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 01 May 2022 | 






